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S290 Poster Session IIwas observed in mice receiving a single dose of silica (3mg silica/
mouse IV) one day prior to GVHD induction as compared to mice
receiving Tcon only (77 days vs. 29 days, respectively, P 5
0.0164). This result correlated with a decrease in Tcon proliferation
as illustrated by whole body bioluminescence imaging (BLI) as well
as ex vivo imaging of lymph nodes, spleen and gastrointestinal tract.
This decrease in T con proliferation was confirmed with CFSE-la-
beled Tcon re-isolated on day 5 after BMT, with 50% of CD4+ T
cells proliferated in the pLN of control mice, yet only 30% prolifer-
ated in silica treated mice (30%, P 5 0.0004). The spleen showed
more proliferation of CD4+ T cells overall, however there was still
a significantly less proliferation in mice receiving silica than in con-
trol mice (79% and 95%, respectively, P5 0.0023). In addition, silica
treatment resulted in less overall inflammation as indicated by anal-
ysis of serum cytokine levels. In particular, significantly less IFNg,
TNF-a, IL-2, IL-4, IL-5,GM-CSF, IL-10, and IL-12were detected
in the serum from mice treated with silica than from control mice.
Together, these results suggest that silica-induced impairment of
macrophage function results in reducedT con proliferation, reduced
inflammation, and prolonged survival after GVHD induction.377
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Background: Hematopoietic stem cell transplantation (HSCT) is
complicated by severe infectious complications during the lympho-
penic period after HSCT, which increases mortality and morbidity.
Anti-thymocyte globuline (ATG) is administered prior to allogeneic
HSCT to reduce risks of graft-rejection and graft versus host
(GvHD). Large interpatient variations in pharmacokinetics (PK) of
ATG have been reported, possibly due to differences in bodysize,
cell numbers prior to ATG, ‘‘the given graft’’, and other patient
characteristics.
Currently, all patients receive the same dose based on bodyweight.
This non-individualized dosage is likely to either increases the risk of
GvHD (by under dosing) or delays post-tranplant immune reconsti-
tution (by overdosing). This study aims to explain the relation
between the above mentioned patient and HSCT related character-
istics and the pharmacokinetics of ATG as a basis to design an
individualized dosing regimen.
Methods: 142 patients, ranging between 4.5 and 80 kg body weight,
who received HSCT between 2004 and 2009 in the two Dutch pedi-
atric hospitals were included. 72 patients received bone marrow, 48
cord blood and 22 peripheral stem cell transplants, containing 23 to
110 CD34+cells. A median dose of rabbit ATG (Imtix) of 10mg/kg
was given in consecutive 4 days. The level of active ATG capable
of binding to T lymphocytes (HUT 78) was measured by quantita-
tive flow cytometry (FACS), total ATG by ELISA. PK analysis was
performed using NONMEM.
Results: Large interindividual variability was observed in PK of
ATG. Preliminary results of the pharmacokinetic model of active
ATG showed a linear relationship between body weight and clear-
ance in children under approximately 20 kg body weight. In children
over 20 kg large variability was observed, which could not be ex-
plained by bodyweight. In 15 Patients, who produced IGG-
antibodies against ATG a more rapid clearance was observed in
comparison with patients who did not form antibodies.
Conclusions: The results of the pharmacokinetic model show that
a fixed dose of 10 mg/kg in all pediatric patients does not lead to
the same exposure of active ATG in all patients ranging 1 month
and 21 years of age. Optimization of the pharmacokinetic will be per-
formed in order to derive a paradigm for individualized dosing, lead-
ing to a more predictable exposure in all patients.378
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Background:True adenovirus infection, but has been reported in 5-
20% of allogeneic hematopoietic stem cell transplant (allo HCT) re-
cipients, with\2% of patients developing severe adenoviral disease.
Adenovirus infection is generally associated with profound immuno-
suppression and a poor outcome. We evaluated the incidence and
significance of adenovirus detection among allo HCT recipients at
our institution between 1999 and 2009.
Methods: Viral culture was used to isolate adenovirus from various
sterile and non-sterile sources. An immunofluorescence assay was
used for confirmation. Definitive infection was the isolation of ade-
novirus from a sterile source with tissue invasion and compatible
clinical presentation. Probable infection represented isolation of
the virus from a non-sterile source without tissue data but with
compatible clinical features. Disseminated disease was defined as
the involvement of . 2 organs.
Results: Seventy-five patientswith at least onepositive adenovirus cul-
ture, representing 1.4%of all alloHCT recipients during the study pe-
riod,were identified.Transplant typeswerematched related (36; 48%),
matched unrelated (22; 29%), haploidentical (9; 12%), and umbilical
cord blood (8; 10%). At the time of adenovirus infection, acute (gra-
deII-IV) or chronic graft versus host disease (GVHD) was present in
18 (24%) and 30 patients (40%), respectively. Sixty-nine of these pa-
tients had probable adenovirus infection while 6 had definitive infec-
tion. Thirteen patients (17%) had disseminated disease. Median time
from allo HCT to adenovirus infection was 4.8 months (range 0.3 to
80).Eightpatients (10%) receivedanti-adenovirus treatmentwithcido-
fovir. The most common clinical manifestations were pneumonia (20,
27%),hemorrhagiccystitis (13,17%),upper respiratory tract infections
(12,16%),andenteritis (11,15%).Medianoverall survivalwas5months
and the 2-year survival was 33%. The presence of acute GVHD (p5
0.001), treatment with methylprednisolone (p5 0.0003) and dissemi-
nated adenovirus disease (p5 0.02) were associatedwith a significantly
shorter overall survival. In contrast, the type of allo HCT, use of cido-
fovir, ATG, or probable vs. definitive adenovirus infection did not have
a significant impact on survival.
Conclusions: Adenovirus infection is relatively uncommon after
allo HCT. Dissemination of adenovirus is associated with a signifi-
cantly poor outcome in patients with acute GVHD and systemic
use of steroids.379
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Background: Bronchiolitis obliterans syndrome (BOS) is a serious
complication of allogeneic bone marrow transplant (BMT). There
is a need for a non-invasive diagnostic test in order to detect BOS
in transplant recipients. KL-6 is a high molecular weight glycopro-
tein classified asMUC1mucin that is expressed on the epithelial sur-
face of type II alveolar cells in the lungs and is present on the surface of
bronchiolar epithelial cells. KL-6 is an active chemotactic factor for
fibroblasts which could play a role in the early pathogenesis of BOS.
Objective:We hypothesize that serum KL-6 levels will be elevated
in subjects with known BOS.
StudyDesign:This is a case control study that employs convenience
sampling for KL-6 samples. It is a multi-center study.
Methods: Serum samples were obtained from 15 subjects that un-
derwent allogeneic BMT and 20 healthy controls between the ages
of 6 months and 30 years. Of the 15 subjects that underwent
BMT, 3 met the criteria for BOS. The definition of BOS was based
upon pulmonary function tests (a sustained drop in FEV1 of 20%
from pre-transplantation baseline) or biopsy. KL-6 levels were
